Kids v Cancer promotes the development of novel pediatric cancer therapies by identifying structural impediments at key junctures in the clinical development and commercialization process and developing strategies to address them IMPACT Some 2% of all bills introduced in Congress are passed into law. We have successfully authored and championed 2. Creating Hope Act: There have been over $4 billion in pediatric vouchers created for drug development expressly for seriously ill kids since 2012 when the Creating Hope Act rare pediatric disease voucher program was passed. RACE for Children Act: Now, 80% of all newly approved cancer drugs that could be studied in children have plans in place for pediatric studies. Before RACE for Children Act in 2017, that number was close to zero. We also built a compassionate use access program and a post mortem brain tumor tissue program.
External link for KIDS V CANCER
2201 WISCONSIN AVE NW STE 320
WASHINGTON, District of Columbia 20007, US
Creating policies to incentivize biopharma to develop drugs for kids — PRV — Give Kids a Chance Act HR 3433 — RACE for Children Act
If the Senate would just include the GIVE KIDS A CHANCE ACT, HR 3433, in the end-of-year package, there would be fewer photos like this. #bipartisan, #PRV, #voucher, #combinations, #childhoodcancer, #nocost2taxpayer, #passedbyHouse
KIDS V CANCER reposted this
Creating policies to incentivize biopharma to develop drugs for kids — PRV — Give Kids a Chance Act HR 3433 — RACE for Children Act
Creating policies to incentivize biopharma to develop drugs for kids — PRV — Give Kids a Chance Act HR 3433 — RACE for Children Act
The HOUSE PASSED THE GIVE KIDS A CHANCE ACT, including the CREATING HOPE REAUTHORIZATION ACT! Today, Monday September 23, 2024, at 4:00 pm, the U.S. House of Representatives passed the Give Kid a Chance Act, HR 3433. The Give Kids a Chance Act ensures that kids with cancer will have studies of combinations of new cancer drugs. This is important because finding new combinations of cancer drugs is the best way to find new cures for kids. The Give Kids a Chance Act also the Creating Hope Reauthorization Act, reauthorizing the priority review voucher program, an incentive program that has resulted in over 60 new drugs for seriously ill kids. Vouchers sell for about $100 million. The Innovations in Pediatric Drugs Act is also part of the Give Kids a Chance Act, increasing funding for pediatric clinical studies at the National Institutes of Health and imposing monetary penalties when companies fail to complete their required pediatric drug studies. YOU DID IT. YOU SPOKE AS THE VOICES OF CHILDHOOD CANCER AND CONGRESS HEARD. We have more steps to go: passage of the Give Kids a Chance Act in the Senate and then signature by the President. But we have reached a critical milestone. Let’s get back to work. Let’s give kids with cancer hope. Let’s give kids with cancer a chance.
Creating policies to incentivize biopharma to develop drugs for kids — PRV — Give Kids a Chance Act HR 3433 — RACE for Children Act
Kids v Cancer is proud to announce Congress's advancement of Give Kids a Chance Act & Creating Hope Reauthorization Act priority review voucher (PRV) program Kids v Cancer is thrilled to announce the successful vote by the U.S. House of Representative’s Energy and Commerce Health Subcommittee to advance not one by two of Kids v Cancer's bills to full Committee: the Give Kids a Chance Act and the Creating Hope Reauthorization Act PRV program. The Subcommittee advanced the bills with a vote of 16-11 to the House of Representatives full Energy and Commerce Committee, with the Creating Hope Reauthorization Act incorporated into the Give Kids a Chance Act. We can't thank our champions enough: Congressman Michael McCaul and Congresswoman Anna Eshoo. We also thank Chair Cathy McMorris Rodgers and Ranking Member Frank Pallone. Next steps are consideration by the U.S. House of Representative’s Energy and Commerce Committee, then a vote of the entire House of Representatives and then on to the Senate. The Give Kids a Chance Act, HR 3433, would authorize the FDA to direct companies with newly approved cancer therapies to study those drugs not only as single drugs, but also in combination with other cancer therapies in children with cancer. This is important because single drug cancer treatments often result in relapses. Cancer cures require multiple therapies. The Give Kids a Chance Act amends the RACE for Children Act, which Kids v Cancer championed to passage to law in 2017. Give Kids a Chance Act has 232 bipartisan cosponsors. The Creating Hope Reauthorization Act, HR 7384, would extend the priority review voucher program, an incentive for companies to develop drugs for kids with rare and life-threatening illnesses. Creating Hope Reauthorization incentives come in forms of vouchers that provide voucher holders rights to faster FDA review for any drug for any disease. Vouchers may be earned by companies that receive FDA approval for a pediatric cancer drug or a drug for other pediatric life-threatening illnesses. Kids v Cancer first championed the program to passage into law in 2012. The program was reauthorized in 2016 and 2020. Unless it’s reauthorized again, the voucher program is due to expire on Sept. 30. Kids v Cancer urges Congress to reauthorize the Creating Hope Act for as long as possible so that the incentive lasts as long as it takes for a drug to be developed. Kids v Cancer will be hosting Climb the Hill days in which children and young adults meet with Members of Congress, in person and by zoom, without parents or other adults. Contact jenn@kidsvcancer.org. A heart-felt "thank you" to all of us, including you, who have worked on and supported these efforts to create incentives for the biotech and pharmaceutical industry to develop new therapies for kids with cancer over the past 15 years, since Jacob died. He would have been 26 this May 21st.